OTCMKTS:ALPMYASTELLAS PHARMA/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ASTELLAS PHARMA/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.42 +0.58 (+3.25 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$18.20Now: $18.42▼$18.4350-Day Range$15.52MA: $16.43▼$17.8452-Week Range$12.48Now: $18.42▼$18.43Volume56,892 shsAverage Volume77,667 shsMarket Capitalization$34.79 billionP/E Ratio19.19Dividend Yield0.88%Beta0.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents; and a research collaboration with NapaJen Pharma, Inc. for the discovery and development of oligonucleotide therapeutics. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ASTELLAS PHARMA/ADR. Previous Next 2.7 Community Rank Outperform VotesASTELLAS PHARMA/ADR has received 211 “outperform” votes. (Add your “outperform” vote.)Underperform VotesASTELLAS PHARMA/ADR has received 179 “underperform” votes. (Add your “underperform” vote.)Community SentimentASTELLAS PHARMA/ADR has received 54.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote “Outperform” if you believe ALPMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend LeadershipASTELLAS PHARMA/ADR is a leading dividend payer. It pays a dividend yield of 0.88%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthASTELLAS PHARMA/ADR does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of ASTELLAS PHARMA/ADR is 16.67 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, ASTELLAS PHARMA/ADR will have a dividend payout ratio of 15.84 % next year. This indicates that ASTELLAS PHARMA/ADR will be able to sustain or increase its dividend. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASTELLAS PHARMA/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.21% of the stock of ASTELLAS PHARMA/ADR is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ASTELLAS PHARMA/ADR are expected to decrease by -0.98% in the coming year, from $1.02 to $1.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASTELLAS PHARMA/ADR is 19.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.96.Price to Earnings Ratio vs. SectorThe P/E ratio of ASTELLAS PHARMA/ADR is 19.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.66.Price to Book Value per Share RatioASTELLAS PHARMA/ADR has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ALPMY Previous Symbol CUSIPN/A CIKN/A Webwww.astellas.com Phone813-3244-3000Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.46Price-To-Earnings Trailing P/E Ratio19.19 Forward P/E Ratio18.06 P/E GrowthN/A Sales & Book Value Annual Sales$11.97 billion Price / Sales2.91 Cash Flow$1.35 per share Price / Cash Flow13.67 Book Value$5.72 per share Price / Book3.22Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees16,617 Outstanding Shares1,888,820,000Market Cap$34.79 billion Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable OTC:ALPMY Rates by TradingView Receive ALPMY News and Ratings via Email Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions How has ASTELLAS PHARMA/ADR's stock been impacted by COVID-19 (Coronavirus)? ASTELLAS PHARMA/ADR's stock was trading at $15.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPMY stock has increased by 17.2% and is now trading at $18.42. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ASTELLAS PHARMA/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ASTELLAS PHARMA/ADR. When is ASTELLAS PHARMA/ADR's next earnings date? ASTELLAS PHARMA/ADR is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for ASTELLAS PHARMA/ADR. How were ASTELLAS PHARMA/ADR's earnings last quarter? ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) announced its earnings results on Thursday, May, 14th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by $0.17. The firm had revenue of $2.87 billion for the quarter. View ASTELLAS PHARMA/ADR's earnings history. When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work? ASTELLAS PHARMA/ADR shares split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split. Has ASTELLAS PHARMA/ADR been receiving favorable news coverage? News stories about ALPMY stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ASTELLAS PHARMA/ADR earned a daily sentiment score of 3.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutASTELLAS PHARMA/ADR. Who are some of ASTELLAS PHARMA/ADR's key competitors? Some companies that are related to ASTELLAS PHARMA/ADR include Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), Bayer (BAYRY), Allergan (AGN), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB) and UCB (UCBJF). View all competitors. Who are ASTELLAS PHARMA/ADR's key executives? ASTELLAS PHARMA/ADR's management team includes the following people: Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.Ms. Linda Friedman, Gen. Counsel & VPDr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56) What is ASTELLAS PHARMA/ADR's stock symbol? ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY." How do I buy shares of ASTELLAS PHARMA/ADR? Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ASTELLAS PHARMA/ADR's stock price today? One share of ALPMY stock can currently be purchased for approximately $18.42. How big of a company is ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR has a market capitalization of $34.79 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe. What is ASTELLAS PHARMA/ADR's official website? The official website for ASTELLAS PHARMA/ADR is www.astellas.com. How can I contact ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000. This page was last updated on 6/2/2020 by MarketBeat.com Staff
